NasdaqGM:LGNDPharmaceuticals
How Bank of America’s Royalty-Focused Coverage At Ligand Pharmaceuticals (LGND) Has Changed Its Investment Story
In early March 2026, Bank of America Securities initiated coverage of Ligand Pharmaceuticals, emphasizing its royalty-focused business model, diversified portfolio of more than 100 assets, and reaffirmed fiscal 2026 earnings and sales guidance.
This coverage spotlighted Ligand’s capital-and-technology partnering approach, which aims to generate high-margin royalty streams across 12 major commercial-stage therapies while limiting traditional biopharma operating risks.
Next, we’ll examine how...